Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
NCT05070403Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2021
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in cutaneous squamous cell carcinoma (cSCC), sponsored by Moffitt Cancer Center. Started Oct 2021; status: active, not recruiting.
02
Drugs
afatinib
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05070403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070403.